Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 28

  • 956 clinical trials
  • 393 recruiting
  • 345 conditions
  • 28 countries

Conditions in this area

345 conditions with trials, the busiest first

Breast cancer168Prostate cancer101Ovarian cancer91Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer41Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer18Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+321

Clinical trials in Reproductive system and breast disorders

956 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

956 clinical trials

Hormone-refractory prostate cancer

Recruiting

Study on the Effects of Acetylsalicylic Acid and Atorvastatin in Patients with Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Institut Gustave Roussy

Breast cancer metastatic+1

Recruiting

Study on the Effectiveness of Trastuzumab Deruxtecan in Patients with HER2-Positive Oligometastatic Breast Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Hormone-dependent prostate cancer+1

Recruiting

Study on Lutetium (177Lu) Vipivotide Tetraxetan to Delay Recurrence in Adult Men with PSMA-Positive Oligometastatic Prostate Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Novartis Pharma AG

Infertility female

Recruiting

Study on the Effect of Ovarian Stimulation with Follitropin Delta, Triptorelin, and Progesterone in Women with Infertility of Advanced Age

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Follitropin Delta
  • Sponsor:Santiago Dexeus Font Fundacio Privada

Infertility

Recruiting

Study on Progesterone and Estradiol for Infertility in Patients Undergoing Hormone Replacement Therapy with Frozen Embryo Transfer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Estradiol
  • Sponsor:Region Midtjylland

Triple negative breast cancer

Recruiting

Study of Bicalutamide and Abemaciclib for Patients with Advanced Androgen Receptor Positive Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:UZ Leuven

Breast cancer

Recruiting

Study on Optimizing CDK 4/6 Inhibitors and Endocrine Therapy for Older Patients with Advanced Breast Cancer Using Abemaciclib, Palbociclib, and Ribociclib

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:65+ years
  • Substances:Abemaciclib
  • Sponsor:Region Oerebro Laen

Prostate cancer

Recruiting

Study of Lutetium (177Lu) Vipivotide Tetraxetan for Patients with High-Risk Localized or Locally Advanced Prostate Cancer Eligible for Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177Lu) Vipivotide Tetraxetan
  • Sponsor:Universitaetsklinikum Essen AöR

Breast cancer metastatic

Recruiting

Study on Lasofoxifene, Fulvestrant, and Abemaciclib for Advanced Breast Cancer in Women and Men with ESR1 Mutation

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib

Ovarian cancer

Recruiting

Study on Improving Ovarian Cancer Diagnosis Using Pyruvic Acid and Gadoteric Acid for Patients Suspected of Having Ovarian Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Gadoteric Acid
  • Sponsor:Aarhus University

Breast cancer metastatic

Recruiting

Study of Fluoroestradiol F-18 and Biomarkers for Women with ER-Positive HER2-Negative Metastatic Breast Cancer After CDK4/6 Inhibitor Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluoroestradiol F-18
  • Sponsor:Institut Curie

Triple negative breast cancer

Recruiting

Study on Early Detection of Triple-Negative Breast Cancer Relapse Using 68Ga-FAPI-46 for Patients at High Risk

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Institut Curie

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab77 clinical trialsLetrozole73 clinical trialsFulvestrant58 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane46 clinical trialsAnastrozole44 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.